EmpiraMed announced it is collaborating with LUNGevity Foundation to gather patient reported outcomes (PROs) from lung cancer patients and their caregivers in a real-world setting. LUNGevity selected EmpiraMed after an extensive vetting process due to its superior and robust platform to gather, store, and analyze patient-level data.
The EmpiraMed platform deploys 100% site-less virtual studies to better evaluate patient experience in the real world. The EmpiraMedTM PRO PortalTM Software Platform will be used to allow patients to participate in clinical studies more easily while compensating them for their data and time in a meaningful way.
"LUNGevity is committed to gathering robust data directly from patients to understand how they are living with and navigating lung cancer so we can better represent them and fill their unmet needs. The high-quality data gathered through the EmpiraMed software platform will also enable researchers to generate hypotheses for future studies," said Andrea Ferris, President & CEO of LUNGevity. "We were impressed by EmpiraMed's software and methods and are excited to partner together to use their platform to gather data from patients around the world."
"We are thrilled to be working with a patient advocacy group as prominent as LUNGevity," said Greg Erman, President & CEO of EmpiraMed. "I believe our innovative technology will be helpful to gather relevant data for researchers to develop new methods to better treat lung cancer patients."